Search

Displaying results 3911 - 3920 of 10000 in total
  1. Drug

    Pamufetinib

    go.drugbank.com/drugs/DB20752
    Investigational

    Pamufetinib is a small molecule drug. The usage of the INN stem '-tinib' in the name indicates that Pamufetinib is a tyrosine kinase inhibitor. … Pamufetinib is under investigation in clinical trial NCT04999761 (AB122 Platform Study). Pamufetinib has a monoisotopic molecular weight of 518.14 Da.

  2. Drug

    Defactinib

    go.drugbank.com/drugs/DB12282
    ApprovedInvestigational

    [L53208,A273943] Defactinib was approved by the US FDA in May 2025 in a co-package alongside [avutometinib] (called Avmapki Fakzynja) for the treatment of recurrent KRAS-mutated low-grade serous ovarian … [L53198,L53208] FAK is important for the integrin-mediated activation of several downstream signal transduction pathways, including those involving RAS/MEK/ERK and PI3K/Akt, and its upregulation is a key

  3. Drug

    Berdazimer

    go.drugbank.com/drugs/DB18712
    Approved

    It is one of the 5 most prevalent skin diseases in the world and the third-most common viral skin infection in children. … Berdazimer is a polymeric substance consisting of a polysiloxane backbone (Si-O-Si bonds) with covalently bound N-diazeniumdiolate nitric oxide (NO) donors.

  4. Drug

    Copanlisib

    go.drugbank.com/drugs/DB12483
    ApprovedInvestigational

    Copanlisib is a selective pan-Class I phosphoinositide 3-kinase (PI3K) inhibitor with preferential activity against the alpha and delta isoforms. … PI3K, a lipid kinase that activates downstream signalling pathways involved in cell survival and growth, that exists in different isoforms and is often overexpressed in hematological malignancies.

  5. Drug

    Capreomycin

    go.drugbank.com/drugs/DB00314
    ApprovedInvestigational

    It is produced by Streptomyces capreolus.

    Categories: Antiinfectives for Systemic Use
  6. Drug

    Sutilain

    go.drugbank.com/drugs/DB09379
    ApprovedWithdrawn

    Sutilain is a member of the keratase family which includes agents such as papain. It is able to dissolve the intercellular matrix which helps with desquamation. … It is currently discontinued.[L2368]

  7. Drug

    Volixibat

    go.drugbank.com/drugs/DB13914
    Investigational

    If approved for use, it will be the first available agent for the treatment of NASH. … Volixibat, also known as SHP626 or LUM002, is an investigational drug that will potentially be used for the treatment of Non-Alcoholic Steatohepatitis (NASH).

  8. Drug

    Iothalamic acid

    go.drugbank.com/drugs/DB09133
    Approved

    Iothalamic acid is an iodine containing organic anion used as a diagnostic contrast agent.

  9. Drug

    Cerivastatin

    go.drugbank.com/drugs/DB00439
    ApprovedWithdrawn

    On August 8, 2001 the U.S. … Food and Drug Administration (FDA) announced that Bayer Pharmaceutical Division voluntarily withdrew Baycol from the U.S. market, due to reports of fatal rhabdomyolysis, a severe adverse reaction from

  10. Target

    Phospholipid-transporting ATPase IA

    go.drugbank.com/bio_entities/BE0001001
    TargetHumans

    Catalytic component of a P4-ATPase flippase complex which catalyzes the hydrolysis of ATP coupled to the transport of aminophospholipids from the outer to the inner leaflet of various membranes and ensures … The flippase complex ATP8A1:CDC50A seems to play a role in regulation of cell migration probably involving flippase-mediated translocation of phosphatidylethanolamine (PE) at the cell membrane (By similarity

    Synonyms: P4-ATPase flippase complex alpha subunit ATP8A1